Repligen Corporation (RGEN) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $131.03. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 1 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of RGEN = $186.82 (+42.6% from the current price, the stock appears undervalued). Analyst consensus target is RGEN = $183 (+39.7% upside).
Valuation: RGEN trades at a trailing Price-to-Earnings (P/E) of 134.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 5.
Financials: revenue is $738M, -1.5%/yr average growth. Net income is $49M, growing at +13%/yr. Net profit margin is 6.6% (thin). Gross margin is 47.1% (-9.8 pp trend).
Balance sheet: total debt is $690M against $2.1B equity (Debt-to-Equity (D/E) ratio 0.33, conservative). Current ratio is 8.37 (strong liquidity). Debt-to-assets is 23.4%. Total assets: $2.9B.
Analyst outlook: 20 / 23 analysts rate RGEN as buy (87%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 49/100 (Partial), Growth 48/100 (Partial), Past 75/100 (Partial), Health 67/100 (Partial), Moat 48/100 (Partial), Future 94/100 (Pass), Income 45/100 (Partial).
